Valtorcitabine

DB06187InvestigationalSmall molecule

Investigated for use/treatment in hepatitis (viral, B).

Chemical structure of Valtorcitabine
Primary indication
Investigated for use/treatment in hepatitis (viral, B).Curator reviewed
Formula / weight
C14H22N4O5 · 326.353 g/mol (avg)

Resolves to

Compound
UNIID5YQG6AQXPCAS380886-95-3ChEMBLCHEMBL2106499
Structure
InChIKeyVFCYZPOEGWLYRM-QCZKYFFMSA-NSMILESCC(C)[C@H](N)C(=O)O[C@@H]1C[C@H](O[C@H]1CO)N1C=CC(N)=NC1=O

What you can answer from here — as of September 13, 2026

1Clinical trialPhase, status and sponsor resolved per trial
Sign in

Which companies are running trials of Valtorcitabine, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In